Display options
Cite
Abenavoli L, DI Renzo L, Guzzi PH, et al. Non-alcoholic fatty liver disease severity, central fat mass and adinopectin: a close relationship. Clujul Med. 2015;88(4):489-93doi: 10.15386/cjmed-595.
Abenavoli, L., DI Renzo, L., Guzzi, P. H., Pellicano, R., Milic, N., & DE Lorenzo, A. (2015). Non-alcoholic fatty liver disease severity, central fat mass and adinopectin: a close relationship. Clujul medical (1957), 88(4), 489-93. https://doi.org/10.15386/cjmed-595
Abenavoli, Ludovico, et al. "Non-alcoholic fatty liver disease severity, central fat mass and adinopectin: a close relationship." Clujul medical (1957) vol. 88,4 (2015): 489-93. doi: https://doi.org/10.15386/cjmed-595
Abenavoli L, DI Renzo L, Guzzi PH, Pellicano R, Milic N, DE Lorenzo A. Non-alcoholic fatty liver disease severity, central fat mass and adinopectin: a close relationship. Clujul Med. 2015;88(4):489-93. doi: 10.15386/cjmed-595. Epub 2015 Nov 15. PMID: 26733747; PMCID: PMC4689242.
Copy Download .nbib Format: NLM
Share it on

Clujul Med. 2015;88(4):489-93. doi: 10.15386/cjmed-595. Epub 2015 Nov 15.

Non-alcoholic fatty liver disease severity, central fat mass and adinopectin: a close relationship.

Clujul medical (1957)

Ludovico Abenavoli, Laura DI Renzo, Pietro Hiram Guzzi, Rinaldo Pellicano, Natasa Milic, Antonino DE Lorenzo

Affiliations

  1. Department of Health Sciences, University "Magna Græcia", Catanzaro, Italy; Division of Clinical Nutrition and Nutrigenomics, Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy.
  2. Division of Clinical Nutrition and Nutrigenomics, Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy.
  3. Department of Medical and Surgical Sciences, University "Magna Græcia", Catanzaro, Italy.
  4. Department of Gastroenterology and Hepatology, Molinette Hospital, Turin, Italy.
  5. Department of Pharmacy, University of Novi Sad, Novi Sad, Serbia.

PMID: 26733747 PMCID: PMC4689242 DOI: 10.15386/cjmed-595

Abstract

AIM: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the general population. Overweight is a common condition in patients with NAFLD, and body composition (BC) assessment is useful to evaluate nutritional status and the efficacy of nutritional strategies. A valid tool for assessing BC is dual-energy X-ray absorptiometry (DXA). Adiponectin has been shown to be relevant to the pathogenesis of NAFLD. The aim of this observational study is to define the relationship between the severity of NAFLD, the central fat mass evaluated by DXA, and the circulating levels of adiponectin.

METHODS: The study was carried out in 31 overweight patients. The degree of liver steatosis was evaluated by ultrasound (US) examination. Anthropometric parameters were measured according to standard methods. Fasting glucose and insulin level were used also to calculate insulin resistance (IR), according to the homeostasis model assessment-insulin resistance (HOMA-IR). The enzyme-linked immunosorbent assay technique was performed to dose fasting serum levels of adiponectin.

RESULTS: NAFLD progression was significantly associated with increased central fat (p<0.05). Using DXA, we quantified the regional distribution of adipose tissue and found the expected association between central fat and the US severity of NAFLD. Serum levels of adiponectin, were inversely related to NAFLD progression (p<0.05).

CONCLUSION: BC evaluated by anthropometry and DXA, may be used as indicator of NAFLD severity in overweight patients. The evaluation of BC in clinical practice, can improve the nutritional strategies and follow-up. In the clinical setting adiponectin may represent a potential marker for the staging of NAFLD.

Keywords: adiponectin; body composition; central obesity; insulin resistance; non-alcoholic fatty liver disease

References

  1. J Endocrinol. 2013 Aug 28;218(3):R25-36 - PubMed
  2. Panminerva Med. 2014 Jun;56(2):189-93 - PubMed
  3. Int J Obes (Lond). 2010 Aug;34(8):1255-64 - PubMed
  4. Biochem Biophys Res Commun. 2012 Aug 31;425(3):560-4 - PubMed
  5. Med Sci Sports Exerc. 1995 May;27(5):776-83 - PubMed
  6. Nutrition. 2014 Jun;30(6):696-701 - PubMed
  7. Radiol Med. 2009 Mar;114(2):286-300 - PubMed
  8. Am J Clin Nutr. 2007 Jan;85(1):40-5 - PubMed
  9. J Plast Reconstr Aesthet Surg. 2009 Jun;62(6):e187-9 - PubMed
  10. J Hepatol. 2013 Oct;59(4):859-71 - PubMed
  11. JAMA. 2001 May 16;285(19):2486-97 - PubMed
  12. Diabetes Care. 2003 Dec;26(12):3320-5 - PubMed
  13. Am J Gastroenterol. 2007 Dec;102(12 ):2708-15 - PubMed
  14. J Endocrinol. 2014 Sep;222(3):R113-27 - PubMed
  15. Metabolism. 2011 Mar;60(3):313-26 - PubMed
  16. Expert Rev Gastroenterol Hepatol. 2015 Apr;9(4):519-27 - PubMed
  17. Hormones (Athens). 2012 Apr-Jun;11(2):178-88 - PubMed
  18. Int J Endocrinol. 2013;2013:865965 - PubMed
  19. Dig Dis. 2010;28(1):155-61 - PubMed
  20. Nat Rev Gastroenterol Hepatol. 2013 Jun;10(6):330-44 - PubMed
  21. Rev Recent Clin Trials. 2014;9(3):134-40 - PubMed

Publication Types